×

Akorn Reaffirms 2015 Revenue and EPS Guidance

LAKE FOREST, Ill., March 10, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX) reaffirms its 2015 EPS metrics issued on February 26, 2015 calling for revenue of between $960 million and $980 million and adjusted diluted earnings per share (EPS) of between $1.88 and $1.98.

Akorn's Chief Financial Officer Tim Dick will present at the Barclays Global Healthcare Conference on Thursday, March 12, 2015 at 10:15 a.m. EDT (9:15 a.m. CDT) at the Loews Miami Beach Hotel in Miami Beach, Florida. Mr. Dick's presentation to investors will be webcast and available to interested investors and analysts.

To access the webcast and replay, go to the Akorn Investor Relations Website at http://investors.akorn.com. The webcast can also be accessed by following the below URL:

http://cc.talkpoint.com/barc002/031015a_ae/?entity=33_RN4JMOJ

An archived version of Mr. Dick's comments will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days following the presentation.

About Akorn

Akorn, Inc. is a specialty pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India where the company manufactures ophthalmic, injectable and specialty non-sterile pharmaceuticals. Additional information is available on the company's website at www.akorn.com.

Forward Looking Statements

This press release includes statements that may constitute "forward-looking statements", including projections of certain measures of Akorn's results of operations, projections of sales, projections of certain charges and expenses, projections related to the number and potential market size of ANDAs, projections with respect to timing and impact of pending acquisitions, and other statements regarding Akorn's goals, regulatory approvals and strategy. Akorn cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. Factors that could cause or contribute to such differences include, but are not limited to: statements relating to future steps we may take, prospective products, prospective acquisitions, future performance or results of current and anticipated products and acquired assets, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the Company or by persons acting on its behalf and in conjunction with its periodic SEC filings. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results.

CONTACT: Investors/Media: Dewey Steadman Executive Director, Investor Relations (847) 582-6923 investor.relations@akorn.com

Source:Akorn, Inc.